Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
HS-10370 / Jiangsu Hansoh Pharma
NCT05367778: Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors	Recruiting	1/2	176	RoW	HS-10370	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Advanced Solid Tumor	04/25	04/26
NCT06594874: A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors	Not yet recruiting	1	350	RoW	HS-10370, Adebrelimab, Cisplatin, Carboplatin, Pemetrexed	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Non-Small Cell Lung Cancer, Advanced Solid Tumors	10/26	01/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
HS-10370 / Jiangsu Hansoh Pharma
NCT05367778: Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors	Recruiting	1/2	176	RoW	HS-10370	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Advanced Solid Tumor	04/25	04/26
NCT06594874: A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors	Not yet recruiting	1	350	RoW	HS-10370, Adebrelimab, Cisplatin, Carboplatin, Pemetrexed	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Non-Small Cell Lung Cancer, Advanced Solid Tumors	10/26	01/27